Redeye’s initial comments on the Q4 report from Waystream.
Redeye states InfraCom’s Q4 2024 report came in better than anticipated and is another print showing...
Q4: +4% org. sales growth, 39% adj. EBITA growth, strong cash flow '25e-'26e adj.
Redeye’s first comments on the Q4 report this morning.
'25e-'26e adj. EBITA down 3% Latent working capital release likely in Q1'25 '25e EV/EBITA of 9x is ~...
Nanexa’s Q4 report did not reveal much new, although the conference call provided welcome clarity on...
Redeye updates its view on Nanologica following the year-end report and recent news flow.
Redeye comments on Th1ng’s latest turmoil—shareholder revolt, board shake-up, and the founder’s ret...
Redeye updates its estimates following Surgical Science’s Q4 2024 report.
Redeye updates its estimates and valuation after OEM’s Q4 2024 report.
Redeye strengthens its positive view of Avensia following an overall solid Q4 report.
Redeye provides its initial take on OEM’s Q4 2024 report, which came in above our estimates.
Redeye comments on Integrum’s directed share issue and we adjust our fair value range per the new nu...
Weaker Q4 than we expected, on higher opex, but ACV was strong We cut '25e-'26e adj.
Fjärde kvartalet utvecklades svagare än vad både Cell Impact och vi förväntade oss.
